Journal of Vaccine Research, 2025, Vol.15, No.1, 45-55 http://medscipublisher.com/index.php/jvr 55 Santaniello A., Napolitano F., Servetto A., De Placido P., Silvestris N., Bianco C., Formisano L., and Bianco R., 2019, Tumour microenvironment and immune evasion in egfr addicted nsclc: hurdles and possibilities, Cancers, 11(10): 1419. https://doi.org/10.3390/cancers11101419 Saxena M., Van Der Burg S., Melief C.J.M., and Bhardwaj N., 2021, Therapeutic cancer vaccines, Nature Reviews Cancer, 21(6): 360-378. https://doi.org/10.1038/s41568-021-00346-0 Socola F., Scherfenberg N., and Raez L.E., 2013, Therapeutic vaccines in non-small cell lung cancer, ImmunoTargets and Therapy, 2: 115-124. https://doi.org/10.2147/ITT.S30813 Theelen W., Pérol M., Cuppens K., Demedts I., Borm F., Biesma B., Wauters E., Colinet B., Buchmeier E., Althoff F., Pons-Tostivint E., Van De Kerkhove C., Moro-Sibilot D., Sibille A., Derijcke S., Skrzypski M., Plumas J., De Vos B., Debruyne C., Cantero F., Adriaenssens S., Renard F., and Vansteenkiste J., 2024, Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC, Cancer Research, 84(7_Supplement): CT021-CT021. https://doi.org/10.1158/1538-7445.am2024-ct021 Wang X.M., Niu Y.P., and Bian F., 2024, The progress of tumor vaccines clinical trials in non-small cell lung cancer, Clinical and Translational Oncology, 27(3): 1062-1074. https://doi.org/10.1007/s12094-024-03678-z Yu J.L., Kong X.N., and Feng Y., 2025, Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation, Cancer Drug Resistance, 8: 21. https://doi.org/10.20517/cdr.2025.14
RkJQdWJsaXNoZXIy MjQ4ODYzNA==